As coronavirus variants increase the spread of the epidemic, accelerating the vaccination campaign becomes a vital issue. Promise of a soon return to normal life and recovery for some sectors on hold because of the health crisis – such as tourism – it becomes a priority in the fight against the coronavirus epidemic. Negotiating is therefore required.
This Monday April 19, 2021, the European Union made a deal with laboratory BioNTech for an extra 100 million doses of the Pfizer and BioNTech vaccine for this year. A transaction making the order totals 600 million doses for 2021, which is the biggest accumulated deal the laboratory ever agreed on.
In the press release, laboratory BioNTech affirms they have met all supply commitments and says that in the second quarter (May to August), 250 million doses will be delivered to the European Union, which is four times more than for the previous quarter. The total of 600 million doses is expected to make it possible to vaccinate at least two thirds of the European population.
